| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MBP; BMPG; MBP1; proMBP |
| WB Predicted band size | 25 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human PRG2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PRG2抗体的3篇参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*"Proteoglycan 2 (PRG2) as a Novel Biomarker in Eosinophilic Inflammation: Detection via Monoclonal Antibody-Based Assays"*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种针对PRG2的单克隆抗体，并验证其在检测嗜酸性粒细胞相关炎症(如哮喘和过敏性鼻炎)中的诊断价值。实验显示，PRG2抗体能特异性识别患者血清和肺组织中的PRG2蛋白，提示其作为炎症标志物的潜力。
---
2. **文献名称**：*"Role of PRG2 in Tumor Microenvironment Remodeling: Insights from Immunohistochemical Analysis"*
**作者**：Chen L, et al.
**摘要**：通过免疫组化技术结合PRG2抗体，研究发现PRG2在多种实体瘤(如乳腺癌和结肠癌)的间质细胞中高表达，可能通过调节细胞外基质促进肿瘤侵袭。抗体的特异性验证为靶向治疗提供了新方向。
---
3. **文献名称**：*"PRG2 Antibody-Based Therapeutic Strategy Attenuates Fibrosis in Experimental Models of Lung Injury"*
**作者**：Yamamoto K, et al.
**摘要**：研究利用PRG2中和抗体干预小鼠肺纤维化模型，发现其能显著降低胶原沉积和炎症细胞浸润。结果表明，靶向PRG2的抗体疗法可能成为纤维化疾病的潜在治疗手段。
---
**备注**：以上文献为示例，实际引用时需以具体检索结果为准。建议通过PubMed或Web of Science以关键词“PRG2 antibody”或“Proteoglycan 2 antibody”查找最新研究。
PRG2 (Proteoglycan 2), also known as eosinophil major basic protein (MBP), is a cationic protein primarily stored in the granules of eosinophils, a type of white blood cell involved in immune responses against parasites and allergic reactions. It plays a dual role: as a cytotoxic mediator, PRG2 directly damages pathogens and host tissues by disrupting cell membranes, contributing to the pathogenesis of inflammatory and allergic diseases such as asthma, atopic dermatitis, and eosinophilic disorders. Additionally, PRG2 can activate immune cells (e.g., mast cells, basophils) and promote tissue remodeling by modulating extracellular matrix components.
Antibodies targeting PRG2 are valuable tools in research and diagnostics. They enable the detection and quantification of PRG2 in biological samples (e.g., via ELISA, immunohistochemistry, or Western blot), aiding in the study of eosinophil activity and disease mechanisms. Clinically, PRG2 antibodies may help diagnose eosinophil-associated conditions or monitor disease progression. Therapeutic applications are also being explored, such as neutralizing PRG2’s cytotoxic effects to mitigate tissue damage in chronic inflammation. However, challenges remain in ensuring antibody specificity and minimizing off-target effects. Overall, PRG2 antibodies bridge basic research and translational medicine, offering insights into eosinophil biology and potential treatments for immune-mediated diseases.
×
